FDA Approves T-DXd Plus Pertuzumab in Metastatic HER2+ Breast Cancer
BREAKING NEWS
Results from the phase 3 DESTINY-Breast09 trial led to the approval of T-DXd plus pertuzumab in unresectable/metastatic HER2+ breast cancer.
| READ NOW |
| READ NOW |